Seizinger Bernd R.

Director Seizinger Bernd R. purchases 100,000 shares at $0.83–$0.85 for $83,454; 8 other insiders also bought within 14 days.

Seizinger Bernd R., a Director at Oncolytics Biotech, completed 2 separate purchases totaling 100,000 shares for $83,454.00 between 2026-02-11 and 2026-02-12 at blended average price $0.83, increasing his holdings by 21.4% to 567.0K shares. Notably, 8 other insiders also bought ONCY within the same 14-day window, forming a cluster buy pattern that suggests coordinated conviction at the current price levels. His cross-ticker track record shows an 80.00% win rate over 90-day holds with average 90d return of +415.4%, though this is his second ONCY purchase in recent weeks (prior buy 2026-01-16) and same-ticker outcome metrics are not yet measurable. The stock currently trades at $1.06, down 25.4% from its 52-week high of $1.42, and the insider's entry at $0.83 represents a price level below the recent average, occurring in a micro-cap with market cap of $84.8M.

Director Bernd R. Seizinger bought 100,000 shares of ONCY at $1.04 (Jan 16); stock now $0.99, down 30.3% from 52-week high.

Seizinger, a director, purchased 100,000 shares at $1.04, increasing his holdings from 366,991 to 466,991 shares (a 27.2% increase). The transaction occurred as the stock is down 30.3% from its 52-week high of $1.42 and trading near the lower end of its $0.33–$1.42 range. His cross-ticker track record shows 5 prior open-market buys with an 80.00% 90-day win rate and an average 90-day return of +415.4%, establishing a strong pattern of buy discipline across holdings. However, this particular trade's timing occurs within a period of recent downward pressure: the stock has declined 16.1% over 90 days and 2.0% over 30 days. The material significance lies in the director's demonstrated historical success identifying value opportunities across his portfolio, now applied to a small-cap biotech ($79.2M market cap) at a price 30.3% below its recent peak.

Director Seizinger bought 10,000 shares at $2.68 (+28.8% holdings); unprofitable APRE faces -64.0% from 52-week high, cluster buy underway.

Director Bernd R. Seizinger purchased 10,000 shares at $2.68 on 2024-10-11, raising his holdings to 44,730 shares (+28.8% vs pre-transaction). The acquisition occurs as APRE trades at $3.05, down 64.0% from its 52-week high of $8.46 and off 3.2% over the past 30 days. Aprea is unprofitable with net income of $-3,470,052.00 and a market cap of $16.6M, operating as a micro-cap biotech under pressure. At the same-ticker level, Seizinger's prior three APRE purchases (2023-06-06, 2023-06-07, 2024-03-13) showed mixed 90-day outcomes: two were well-timed (positive returns at the 90-day mark) but the most recent buy on 2024-03-13 underperformed (-38.8% over 90 days). A cluster pattern of three other insider buys within the past 14 days adds incremental signal that management perceives value, though the timing pattern at this specific ticker remains uneven and fundamentals remain negative.